ASTRAZENECA PLC DL-,25/ GB0009895292 /
| 2024-11-04 4:00:11 PM | Chg. -0.75 | Volume | Bid2024-11-04 | Ask2024-11-04 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 131.35EUR | -0.57% | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 205.14 bill.EUR | - | - |
Newsfile Corp
3:00 PM
Elsevier Supports Pistoia Alliance in Accelerating Safe and Responsible AI Adoption in Drug Discover...
GlobeNewswire
08-12
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire
08-08
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire
08-06
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
06-26
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
06-18
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire
06-18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06-13
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire
05-08
Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire
05-06
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire
05-02
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
